TTrialPathMatch Me to Trials
← Back to trials
RecruitingTranscatheter Aortic Valve Replacement (TAVR)Aortic-StenosisAortic Insufficiency

Prospective, Long-term Evaluation of the SAPIEN 3 Ultra RESILIA Valve

Eligible age

18+ yrs

Accepts

All genders

Locations

0 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

Evaluation of clinical outcomes and valve performance of the SAPIEN 3 Ultra Resilia (S3UR) valve over 10 years.

Sponsor: Institut für Pharmakologie und Präventive Medizin

You may qualify if…

  • ✓ Adult patients (≥18 years)
  • ✓ Patients with severe aortic stenosis undergoing transfemoral TAVI on their native valve with S3UR valve
  • ✓ Patient is willing to attend the follow-up visits up to 10 years at the center

You may not qualify if…

  • ✕ Lack of written informed consent
  • ✕ Emergency procedure
  • ✕ Pregnancy at time of TAVI
  • ✕ Critieria for long-term observation (1y-10y):
  • ✕ Technical success at exit from procedure room (VARC-3):
  • ✕ Freedom from mortality
  • ✕ Successful access, delivery of the device, and retrieval of the delivery system
  • ✕ Correct positioning of a single prosthetic heart valve into the proper anatomical location

Source: ClinicalTrials.gov · NCT06953206 · last updated 2026-07-30